10 results about "MISCELLANEOUS TUMORS" patented technology

The invention relates to the technical field of hospital image analysis, provides a PET image generation method, system and device based on 3D wavelet transform Brownian bridge diffusion and a storage medium, and solves the technical problem of how to improve the accuracy and reliability of PET images in the existing nasopharyngeal carcinoma medical image analysis process. MRI and PET images are divided into low-frequency structure information and high-frequency detail information through wavelet decomposition, then global semantics and local details are modeled through double-branch Brownian bridge diffusion, and finally fusion is implemented through inverse wavelet transform to obtain a more stable and more accurate final three-dimensional synthesis PET image. The method is suitable for nasopharynx cancer or other tumors or other medical image analysis processes.

The invention discloses application of a novel intestinal cancer detection kit of RBM15, and relates to the technical field of biological detection, the application of the RBM15 as the intestinal cancer detection kit in CRC molecular markers is characterized in that 36 pairs of CRC tissues and para-carcinoma samples are detected through qRT-PCR, expression data of RBM15 and corresponding serum tumor clinical indexes in 36 cases of CRC clinical tissues are analyzed through Spearman correlation, and the RBM15 and the expression data of serum tumor clinical indexes in the CRC clinical tissues are analyzed. Based on CRC in a TCGA database and expression data of a normal sample, an ROC curve of RBM15 and other tumor related indexes is drawn, an AUC value is calculated, and it is shown that the diagnosis efficiency is superior to that of part of traditional serum markers. As a novel CRC molecular marker, the RBM15 provided by the invention has remarkable advantages in the aspect of constructing a high-sensitivity and high-specificity detection kit, can be used for early diagnosis and prognosis evaluation, provides a new target for developing a treatment strategy of targeting m6A modification, and has wide clinical application and transformation prospects.

The invention relates to a method for detecting low-frequency mutation in cfDNA and application of the method, a mutation detection method with high sensitivity and high specificity is established through a TARGET directional enrichment technology, and the problems that traditional NGS is high in false negative rate, inaccurate in quantification and the like in ultralow-frequency mutation detection are solved. The technical breakthrough not only provides a new tool for early screening and drug resistance monitoring of lung cancer, but also lays a methodological foundation for liquid biopsy application of other tumors.

The disclosure provides a method, a system, an apparatus, and a computer program product for determining IFP, IFV, and fluid flow inside tumors. In one example, a method for estimating tumor parameters is disclosed. This method includes: (1) receiving image data from a tumor, (2) obtaining strain data of the tumor from the image data, and (3) determining a tumor parameter, such as IFP and IFV, employing the strain data and an analytical model. Additional tumor parameters can be determined employing the strain data and other analytical models. The additional tumor parameters include compression-induced fluid pressure, velocity and flow inside the tumor, parameter ? employing the fluid pressure, the ratio between vascular permeability and interstitial permeability, and the ratio of peak IFP and effective vascular pressure. Each of these parameters can be employed for analyzing, monitoring, treating, testing, etc., tumors or the effects of drugs on the tumors.

The invention relates to a method for detecting low-frequency mutation in cfDNA and application of the method, a mutation detection method with high sensitivity and high specificity is established through a TARGET directional enrichment technology, and the problems that traditional NGS is high in false negative rate, inaccurate in quantification and the like in ultralow-frequency mutation detection are solved. The technical breakthrough not only provides a new tool for early screening and drug resistance monitoring of lung cancer, but also lays a methodological foundation for liquid biopsy application of other tumors.

The application discloses a biological macromolecular drug for tumor treatment, which has tissue protein adhesion, can continuously improve the oxidative stress environment of a tumor site by prolonging the time at the tumor site, can inhibit tumor growth by tumor microenvironment regulation, can also be used as an auxiliary therapeutic agent to enhance the curative effect of other tumor treatments, and has a good clinical transformation prospect.

The invention discloses a method for constructing a lung adenocarcinoma diagnosis model based on immunoassay and interpretable machine learning, and belongs to the field of biomedical engineering.The method comprises the steps that data acquisition and preprocessing are conducted, specifically, an experimental data set containing lung adenocarcinoma sample gene expression data, survival data, immune cell infiltration abundance data and immune checkpoint gene data is acquired, the verification data set comprises expression data of lung adenocarcinoma tumor tissue and normal tissue samples, and preprocessing the data; according to the invention, genes are screened through immunization-survival dual association, and the diagnosis specificity is improved in combination with lung adenocarcinoma immune microenvironment characteristics; according to the invention, contribution (such as specific influence of CDCA8, SPAG5 and other genes on diagnosis) of a core gene is determined through an SHAP model, and the problem of black box in traditional machine learning is solved; therefore, the method can be used for lung adenocarcinoma diagnosis, and an immune correlation analysis and multi-algorithm screening framework can be popularized to construction of diagnosis models of other tumors.

The invention discloses a method for detecting a tumor marker CA72-4 based on a sandwich-type electrochemical immunosensor, which comprises the following specific steps: constructing an rGO-TEPA / ZIF67-ZIF8 / Au functional modification layer as a CA72-4 capture antibody Ab1 fixing carrier by using a glassy carbon electrode as a substrate, and coupling AuPdRu ternary nanoparticles and a CA72-4 detection antibody Ab2 to form a signal probe; specific recognition of the tumor marker CA72-4 is realized through an Ab1 / CA72-4 / Ab2 sandwich structure, and high-sensitivity selective detection of a target antigen, namely the tumor marker CA72-4, is realized by utilizing an amplified current signal of bimetal / trimetal synergistic catalysis H2O2 reaction. By combining multi-metal catalysis and the high-conductivity composite substrate, bidirectional signal amplification is realized, and the electrochemical immunodetection sensitivity is remarkably improved. The method is simple and convenient to operate, high in sensitivity and rapid in response, and can be popularized and applied to detection of other tumor markers.

Provided is a method for treating metastatic disease or any other tumor that cannot easily or readily localized or localized at all using immersion mechanotherapy. The method includes providing a vessel containing an amount of medium for immersing at least a portion of a subject, and applying one or more programmed cycles of ultrasound waves to the subject through the medium for a pre-determined period of time. Also provided is a device for implementing the immersion mechanotherapy.

The invention discloses a fluorescence in situ hybridization joint detection probe for an MDM2 gene and a CDK4 gene and application of the fluorescence in situ hybridization joint detection probe. The joint detection probe comprises a first probe and a second probe, the first probe is obtained by labeling fluorescein on genome segments corresponding to CTD (Complementary Type Division)-2033G5, RP11-159C11 and RP11-630N19 which are cloned by covering BAC (Bacterial Amplification Controller); the second probe is obtained by labeling fluorescein on genome segments corresponding to RP11-936I7 and RP11-970A5 which cover BAC clones, the amplification conditions of MDM2 and CDK4 genes are simultaneously detected by utilizing the probe through a fluorescence in situ hybridization method, and the probe can assist in identifying lipoma and liposarcoma. Therefore, more accurate and effective benign and malignant differential diagnosis and molecular typing of the adipose-derived tumors can be realized; and the kit can also be used for screening potential people with MDM2 and CDK4 amplification in other tumors, and is beneficial to realizing precise treatment on patients.